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DNA-mediated or DNA- based immunization, with
the understanding that the objective is not to raise
an immune response to the DNA itself.
This method is conceptually sound and experi-
mentally straightforward; however, its most novel
aspect is that it works at all! It was not expected
that pure plasmid DNA could be taken up by cells,
after parenteral introduction in a simple saline
solution (4), to levels allowing expression of enough
protein to induce an immune response. A more
radical method of introducing DNA involves the
bombardment of DNA-coated gold particles. When
applied to the skin, these particles produce good
immune responses with much less DNA than is
required by other routes, such as intramuscular
or intradermal needle injection (5). More esoteric
still is the application of pure DNA solution (as
nose drops) to the nasal membranes, which has
been reported to work (5) but is perhaps too inef-
ficient for further consideration.
DNA vaccines have distinct advantages: They
can be manufactured far more easily than vaccines
composed of an inactivated pathogen, subcellular
fraction, or recombinant protein. Since almost all
plasmids can be manufactured in essentially the
same way, substantial economies of scale can be
achieved. DNA is very stable and resists tempera-
ture extremes; consequently, the storage,
transport, and distribution of DNA-based vaccines
are more practical and less expensive. In addition
to the commercial, there are vaccine research and
development considerations. It is now possible to
change the sequence of an antigenic protein, or to
add heterologous epitopes, by simply introducing
mutations to the plasmid DNA. The immunoge-
nicity of the modified protein can be directly
“But there is no single problem that is more
pressing than our fast-deteriorating relations with
the microbial world” wrote Barbara Culliton (1),
the editor-in-chief of Nature Medicine, at the end
of 1995. This stark statement concluded her com-
ments on, among other threats, the reemergence
of cholera and plague, the growing number of Lyme
disease cases, and humanity’s occasional but fre-
netic duels with Ebola virus. What if one day an
Ebola-infected traveler makes it to the boarding
lounge and embarks on an airplane? As pointed
out by David Heymann, director of the World
Health Organi-zation’s new Division of Emerging
Diseases, the virus would spread to far corners of
the world (2) with dramatic consequences. This
scenario has already been played out with human
immunodeficiency virus (HIV). Vaccines have tra-
ditionally been used as weapons against health
threats. In the case of HIV infection, the basis for
one has not yet been clearly delineated. For scien-
tific, commercial, and practical reasons vaccines
cannot solve all the problems posed by emerging
infectious organisms. However, novel and power-
ful methods for vaccine research, and possibly for
vaccines themselves, hold some promise in our
efforts to curb emerging disease threats. These
methods involve the deliberate introduction of a
DNA plasmid carrying a protein-coding gene that
transfects cells in vivo (albeit at a low efficiency)
and expresses an antigen causing an immune re-
sponse (3). This procedure, known as a DNA
vaccine, is perhaps better described as
A novel and powerful method for vaccine research, colloquially known as DNA
vaccines, involves the deliberate introduction into tissues of a DNA plasmid carrying
an antigen-coding gene that transfects cells in vivo and results in an immune
response. DNA vaccines have several distinct advantages, which include ease of
manipulation, use of a generic technology, simplicity of manufacture, and chemical
and biological stability. In addition, DNA vaccines are a great leveler among re-
searchers around the world because they provide unprecedented ease of experi-
mentation. To facilitate diffusion of information, an Internet site has been established
called THE DNA VACCINE WEB (URL:http://www.genweb.com/dnavax/dnavax.html). In
this review, a brief survey is undertaken of the experimental models and preclinical
work on DNA vaccines to contribute to a greater awareness of the possibilities for
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assessed after injecting the plasmid DNA. This
simple method could increase considerably our un-
derstanding of the immune response to antigens.
In addition, both in vaccine research and in
actual use, DNA-mediated immunization is the
great leveler among researchers around the world.
It is easy to use because once the protein coding
sequences are cloned into a suitable expression
vector, the direct introduction of the plasmid vec-
tor (into mice for example) allows experimental
assessment of the immune response and its con-
sequences, without further experimental steps
such as the preparation of a recombinant protein
as antigen.
Because it is so straightforward and requires
only simple molecular biologic techniques, the
method should be practical in many laboratories
around the world. It would be unrealistic to deny
that certain diseases are not of great interest to
large pharmaceutical firms. Moreover, even when
triumphs over disease are achieved, as in the case
of hepatitis B virus (HBV) infection (6), market-
ing strategies can exclude the vaccine from regions
where it would do the most good. DNA-mediated
immunization can be used in countries that can-
not implement more complicated and expensive
strategies.
What if DNA vaccine research could be car-
ried out worldwide by a generic technology, where
human creativity adds substantial value to the
work? This short review outlines the possibilities
offered by DNA-mediated immunization.1 I will
review experimental models and preclinical work
on DNA vaccines and discuss new developments
that are based on the idea that DNA delivery can
be used to induce immune response to proteins.
Animal Models of DNA Vaccines
Various experimental models of DNA vaccina-
tion have been reported (Table 1). Most of the
pathogens studied have been viruses, which is con-
sistent with the method used: since the genes
transferred by the plasmids require the host cel-
lular machinery to be expressed, DNA-based
immunization most resembles a virus infection.
However, genes from other microorganisms have
also been used with success. The types of polypep-
tides expressed are often the envelope proteins
of viruses, but various proteins have been used.
Indeed, it is not obvious what aspects of a protein
produce an effective immune response by this un-
usual method of antigen delivery.
The immune responses obtained are clearly
broad-based when they have been well character-
ized. In several models, antibodies are
reproducibly induced, and the antibodies ulti-
mately are of the immunoglobulin G (IgG) type,
indicating a T-dependent class switch. In the case
of immunization for HBV surface antigen, the fine
specificity of the humoral response in mice mim-
ics, to a certain extent, that observed during
infection in humans (12). T-cell proliferation and
cytokine secretion have been studied in several
models, and the cytokine profile indicates a Th1
type response, characterized by the secretion of
interleukin-2 and g-interferon. The immune re-
sponses can be remarkably long lasting; however,
the duration of the immune response does not ap-
pear to have any deleterious effects on the animals
because they are protected against challenge long
after immunization (41). Also, in some cases, as in
the DNA-mediated immunization against HBV sur-
face antigen, antibody levels reach a plateau at
titers of about 104 and remain stable for at least
18 months. If the mice are boosted with a second
DNA injection at 7 months, a further 10-fold in-
crease in titer can be obtained (14).
Cytotoxic T lymphocytes (CTL) are invariably
induced to class I epitopes of the proteins encoded
by the transferred genes. These CTL responses
can be quite strong (10), and DNA-mediated im-
munization can circumvent haplotype-linked
nonrespon- siveness (13). Cytotoxic immune re-
sponses are thought to be important in clearing
viral infections because this type of T-cell response
allows the immune system to recognize virally in-
fected cells and destroy them, thus removing the
virus.
What is surprising about the induction of CTL
with DNA-mediated immunization is that either
professional antigen-presenting cells have been
successfully transfected, or the free protein can
be processed more effectively with CTL induction
than with a classical immunization protocol. A large
body of immunologic evidence suggests that only
professional antigen-presenting cells can prime T
lymph- ocytes in the first stages of the immune
response. Thus, the transfection of muscle fibers,
for example, would not normally be expected to
lead to such efficient immune responses. Solution
of this enigma should provide insight into some
fundamental immune processes. In the meantime,
DNA-based immunization is an excellent and
1 An Internet site, THE DNA VACCINE WEB (URL http://www.genweb.com/Dnavax/dnavax.html), provides journal references, abstracts,
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Table 1. Animal models of DNA vaccines 
Pathogen Antigen Animal species Reference
Bovine herpesvirus Glycoprotein Cattle,| mouse (7)
Hepatitis B virus Capsid protein (core antigen) Mouse (48)
Hepatitis B virus Envelope protein (surface antigen) Mouse (3, 8-14, 53)
Rabbit
Rat
Chimpanzee*
Hepatitis C virus Core/nucleocapsid Mouse (12, 15)
Herpes simplex virus Glycoprotein B Mouse|* (16-18)
Glycoprotein D
ICP27
Human immuno- Envelope glycoprotein Mouse (19-22)
   deficiency virus-1 gp160 Nonhuman primates
Noninfectious particles
House dust mite Allergen Rat* (52)
Influenza virus Hemagglutinin Chicken* (23-29)
Matrix protein Ferrets*
Nucleoprotein Mouse*
Nonhuman primates*
Leishmania major Major surface glycoprotein Mouse* (50)
Lymphocytic chorio- Glycoprotein Mouse|*@ (30-32)
   meningitis virus Nucleoprotein
Mycobacterium M. leprae hsp65 Mouse| (33)
   tuberculosis
Mycoplasma pulmonis M. pulmonis DNA Mouse* (34, 35)
M. pulmonis DNA expression library
Papillomavirus Major capsid protein L1 Rabbit* (51)
Plasmodium yoelii Circumsporozoite protein Mouse| (36-38)
Rabies virus Glycoprotein Mouse* (39-41)
Simian immuno- Env, gag Monkey (49)
   deficiency virus
Schistosoma Paramyosin (Sj97) Mouse (42)
   japonicum
The symbols | and * refer to reports of partial or complete protection, respectively, to challenge by the infectious agent. In one case, enhanced immunopathology (@) after
intracranial viral challenge has been reported (32).
Updated versions of this table can be found on THE DNA VACCINE WEB site (URL http://www.genweb.com/Dnavax/dnavax.html) where links are provided to the Medline
abstracts of most references. See also a compendium of recent articles on DNA vaccines in a special issue of the Annals of the New York Academy of Sciences, Volume 772
(New York Academy of Sciences Conference: “DNA Vaccines: A Novel Approach to Vaccination,” Arlington, VA, April 7-9, 1995). The Medline abstracts of the articles in this
issue can be found on THE DNA VACCINE WEB.
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simple tool to achieve CTL responses for which
efficient methods have been needed for years.
One of the first uses of DNA-mediated immu-
nization was to induce such cytotoxic cellular
immunity to a conserved protein of influenza A
virus to determine if overcoming its seasonal varia-
tion was possible. Ulmer et al. (26), obtained
cytotoxic T    lymphocytes directed against the
conserved influenza nucleoprotein, which pro-
tected mice against the disease, even when they
were challenged with a heterologous virus carry-
ing a different hemagglutinin but the same
nucleoprotein sequence.
The crucial point, however, is the ability of
DNA-based immunization to protect animals from
infection upon challenge, and this has been dem-
onstrated in several model systems, particularly
with influenza and rabies viruses, as well as Myco-
plasma pulmonis and Plasmodium yoelii.
Donnelly et al. (29) have shown that a mixture of
plasmids can be used to induce antibody to the
influenza hemagglutinin surface protein and cyto-
toxic immunity to the viral nucleoprotein and
matrix protein. This DNA vaccine protected fer-
rets and African green monkeys against viral
challenge by using an antigenically distinct human
influenza virus more effectively than the contem-
porary commercial vaccine. The influenza model
has now been the subject of much preclinical work,
and human trials are in progress.
One human trial uses plasmid vectors express-
ing HIV-1 genes delivered to HIV-seropositive
persons by intramuscular injection. This protocol
uses Marcaine to facilitate DNA uptake, although
the mechanism of this effect has not been clearly
delineated (20). More clinical trials will likely be
initiated since plasmid DNA is now considered an
innocuous substance compared with other genetic
vectors used in therapy.
Further Questions on Methods
Most studies listed in Table 1 have used intra-
muscular needle injection to deliver DNA;
however, intradermal particle bombardment works
very well (provided that one has access to biolistic
apparatus). Intradermal particle bombardment
may ultimately work better than intramuscular
injection in primates, including humans, since ex-
tensive connective tissue in muscle may impede
DNA diffusion and transfection in larger mammals
that do not lead sedentary lives in cages.
In most of our own experimental work (8-12),
we have used a protocol that induces muscle re-
generation and increases the number of transfected
muscle fibers (43), presumably because of improved
diffusion of the DNA and better transfection effi-
ciency of immature fibers. The actual protocol is
probably not suitable for routine prophylactic vac-
cination in humans, although it could be considered
for therapeutic immunization. Nonetheless, this
model system shows that muscle fibers can take
up DNA better under some circumstances, and
further understanding of this process may im-
prove formulations for DNA uptake in muscle.
Such improvements will almost certainly be a pre-
requisite for intramuscular DNA vaccination in
humans. The improved uptake of DNA in regener-
ating muscles composed of immature fibers also
suggests that newborn mammalian muscle may
also take up DNA more effectively than adult
muscle. Since improving childhood vaccination
programs is a goal, this characteristic may be an
important consideration in the use of DNA vac-
cines, if they can be used for children.
The regeneration protocol is particularly use-
ful for scientists who are beginning research with
DNA-mediated immunization. The use of available
control plasmids to inject DNA for validating the
procedure is also an important consideration. The
various steps that can be taken to achieve repro-
ducible immunization with plasmid DNA transfer
have been discussed (44). Careful attention to the
details of the intramuscular injection protocol
(43,45) can make a substantial difference in the
outcome.
Vaccine Development and the Limits of the
Protective Immune Response
A successful vaccine must confer protective
response to the recipient, and therefore, the lim-
its of the immune response must be known. This
knowledge can be purely empirical, as in the case
of the first polio vaccines for which the precise
protective epitopes were not known. Such knowl-
edge is not required when using a killed or
attenuated viral preparation. In contrast, for re-
combinant vaccines a single protein should induce
an immune response that will provide sterilizing
immunity; this is also true for DNA vaccines and
represents a major conceptual limitation in the
use of this approach for vaccination. Although mix-
tures of individual proteins or their genes can be
envisioned, in the case of recombinant protein vac-
cines this would be pro- hibitively complicated and
expensive. For DNA vaccines this is far easier to
imagine since the injected material is always DNA,
and no matter what genes are carried by the plas-
mid, the production process is the same.Emerging Infectious Diseases Vol. 2, No. 3—July-September 1996
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The only human vaccine that uses a recombi-
nant protein as its basis is that against HBV, which
has been used for nearly 10 years. Such a high-tech
vaccine was possible because empty viral particles,
from the plasma of persons chronically infected
with HBV, could be purified and used to induce
humoral immunity against the so-called surface
antigen that would protect against infection. The
plasma-derived particles are still used as a vac-
cine in many countries, in part because of the cost
of the recombinant product (6). The envelope pro-
teins of viruses are always good targets for
inducing protective immunity.
However, this rational clearly breaks down in
the case of a virus, such as HIV, which mutates so
rapidly, apparently in response to immune pres-
sure. The fundamental knowledge required to
determine what would comprise a potential HIV
vaccine is still lacking, and therefore, it is unlikely
that a vaccine can be developed until further ba-
sic research provides more insight. Thus HBV and
HIV illustrate two extremes in vaccine develop-
ment: with HBV a simple antibody response to a
single antigen neutralizes the virus, whereas with
HIV some form of cytotoxic immune response is
probably necessary. DNA-mediated immunization
has a role to play in further research.
Expression Library Immunization
An attempt has been made to use
DNA-mediated immunization to develop a system-
atic method for producing a vaccine. Barry et al.
(34) took advantage of the very small amounts of
DNA required with the particle bombardment
method (5,46). Since a single nanogram of DNA
coated on the gold particles can induce an immune
response, one microgram can potentially introduce
a thousand different genes. On this basis, a library
of gene fragments was prepared from Mycoplasma
pulmonis by cloning the genomic DNA into a plas-
mid expression vector. Since this organism has a
relatively small genome (about 106 base pairs),
enough of the total DNA protein-coding sequences
might be expressed to induce immunity to the
pathogen. Since only a small part of the genetic
complement of the organism is expressed and ex-
pression is mostly from only a fragment of genes
and not entire functional proteins, pathogenic ef-
fects would be avoided, while all the advantages
of broad-based immunity produced by a DNA vac-
cine would be present.
Protection against M. pulmonis has been
achieved after immunization with different expres-
sion libraries (34). The next steps could consist of
using the method to screen for the gene or genes
responsible for protective immunity. Seen in this
light, this approach solves the problems of having
a more general way to determine the limits of pro-
tection, which is vital in establishing what the
protein or DNA composition of a vaccine would
be. The search for a single gene, or a small num-
ber of genes, should be facilitated by the use of
the DNA-based immunization method. However,
if many gene products are required to confer pro-
tection, defining the correct mixture may not be
straightforward.
This discussion raises another consideration.
From several points of view (at least regulatory
and manufacturing), a vaccine must contain de-
fined components. Therefore, the expression
library immuni- zation approach cannot be used
with simple mixtures of uncharacterized gene frag-
ments. Although in principle it is possible, would
anyone be prepared to have a human vaccine com-
posed of an undefined mixture of HIV or Ebola
virus gene fragments that seemed to confer pro-
tection in animal models? Once again, the simple
method means that further creative   research
may rapidly provide insight into vaccine design.
What If an Ebola Outbreak Threatens the World?
Let us take the most provocative scenario to
illustrate what can perhaps be done, in principle
and in practice, in the face of a rampantly infec-
tious viral disease. When preventive measures
against an agent like Ebola virus are needed on an
emergency basis, speed is imperative. The
filoviruses Ebola and Marburg are extremely
pathogenic, causing a fulminating febrile hemor-
rhagic disease; they grow fast, kill most cells, and
the infected person bleeds to death, usually within
48 hours of infection.
These viruses are enveloped filamentous par-
ticles with a nonsegmented negative-strand RNA.
The genes of both members of the filovirus genus,
the Marburg virus group and the Ebola group, have
already been cloned and sequenced. There does
not, as yet, seem to be any great variation among
the proteins sequences for a given virus; however,
Ebola and Marburg are not highly related sero-
logically. The filoviruses are similar to
paramyxoviruses, such as the respiratory syncy-
tial virus.
This basic molecular information is enough for
testing the ability of one or more of the genes to
induce an antibody and CTL response that might
help protect against disease. One would choose
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pathology of the virus, but this should be rela-
tively easy, since the growth potential of the virus
largely accounts for its extreme toxicity. One op-
tion is the gene encoding the glycoprotein, a viral
membrane protein requiring glycosylation for its
native structure. Such glycosylation might be im-
portant for the antigenicity of the protein if it is
to mimic the filamentous envelope of the virus.
Here, the fact that DNA vaccination involves syn-
thesis of the protein in the cells of the mammalian
recipient of the DNA vaccine means that the ap-
propriate glycosylation pattern can be produced.
If Ebola or Marburg, or a related filovirus, es-
caped a restricted ecologic niche, the following
scenario might unfold. If the emerged virus is
found (by serologic testing) to be one of the exist-
ing, characterized ones, existing cloned genes could
be used. Otherwise, a virus isolate would need to
be obtained, and the genes would need to be cloned.
Cloning can be accomplished easily since related
genes are available for probes in molecular clon-
ing experiments.
Since one strategy for prophylactic vaccina-
tion is to induce a humoral response to the outer
coat of the virus and block entry to the cells, clon-
ing would allow an attempt to quickly counter the
virus infection or at least to slow down its spread
in the organism or within the population. A
full-length envelope glycoprotein gene could be iso-
lated from the cloned virus genome (perhaps by
polymerase chain reaction) and cloned directly into
a suitable DNA vaccine plasmid vector. A GMP
production run could be carried out, perhaps within
a week, and DNA vaccine could begin to be dis-
tributed to areas most critically at risk.
The above scenario assumes that DNA vac-
cines will be accepted for use in humans, which
seems likely for high-risk situations, and that the
basic method for preparing GMP-grade plasmid
DNA is available, which is currently the case. Since
August 1995, a collaboration between Qiagen
(Hilden, Germany) and Pharos (Seraing, Belgium)
has offered full-GMP production of plasmid DNA
to companies and the scientific community in gen-
eral. The molecular method needed to rapidly go
from a virus isolate to the vaccinating plasmid vec-
tor should represent only a relatively minor
bottleneck to the development of an urgently
needed vaccine, at least compared with any other
approach used before. It is not surprising that
Bernard Dixon, writing in Bio/Technology (47), has
called DNA vaccines “the third vaccine revolution.”
This review poses questions about DNA vac-
cines and suggests that the answers lie in new
methods of research and development. If
DNA-mediated immunization were used in all coun-
tries that have expertise in molecular biology, novel
vaccines would be developed. Ultimately, a major
goal of the DNA vaccine approach for public health
might well be to bring vaccine development within
the reach of researchers working on infectious dis-
ease problems in which there is no great
commercial interest. If DNA vaccines come into
widespread use for public health applications, vac-
cines for many diseases could be produced rapidly
since, in the end, the product is simply a DNA
plasmid.
What if such a method were used for human
vaccination? The cost of production and delivery
of vaccines would be reduced, thus allowing vac-
cines to reach areas of the world somewhat
deprived of preventive public health measures,
particularly the recent biotechnologic methods. If
new infectious diseases appear in the future, as
they surely will, perhaps these new tools will be
used to combat them more effectively.
Today’s research method can be tomorrow’s
vaccine. DNA vaccines will be within the means of
many more populations and countries since full
GMP production technology will be both simpler
than technology for other products and far more
available to research scientists. A little more than
2 years stood between the first published descrip-
tion of a DNA vaccine and the beginning of the
first clinical trial, which indicates that the neces-
sary infrastructure for producing DNA vaccines
was rapidly put in place. But more importantly,
this short time span bodes well for the ability of
public health agencies all over the world to bring
scientific research to bear on diseases relevant to
their own situation and to disease prevention.
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